Decheng Capital »

4d Molecular Therapeutics In shares owned by Decheng Capital

Quarter-by-quarter ownership of 4d Molecular Therapeutics In (FDMT) shares owned by Decheng Capital from 13F filings

Historical chart of Decheng Capital investment in 4d Molecular Therapeutics In

Tip: Access up to 7 years of quarterly data

All positions including 4d Molecular Therapeutics In held by Decheng Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in 4d Molecular Therapeutics In by Decheng Capital

Quarter filed Position value Share count Share price at filing
2024-06-30 $7.3M 348k 20.99
2024-03-31 $11M 348k 31.86

More positions owned by Decheng Capital

Cg Oncology (CGON)
Nuvation Bio (NUVB)
Arcus Biosciences Incorporated (RCUS)
Zentalis Pharmaceuticals (ZNTL)
Krystal Biotech (KRYS)
BeyondSpring SHS (BYSI)
Illumina (ILMN)
Merus N V (MRUS)
Phathom Pharmaceuticals (PHAT)
Newamsterdam Pharma Co Nv (NAMS)
Helix Acquisition Corp
4d Molecular Therapeutics In (FDMT)
Crinetics Pharmaceuticals In (CRNX)
Cytokinetics (CYTK)
Legend Biotech Corp- Adr (LEGN)

View all positions for Decheng Capital

Top funds holding 4d Molecular Therapeutics In

RA Capital Management
BlackRock
VR Adviser
Goldman Sachs Group
Deep Track Capital
BVF
Henderson Group
Viking Global Investors
Vanguard Group
State Street Corporation
Polar Capital Holdings
Morgan Stanley
Novo A/S
Redmile Group
Geode Capital Management

View all funds holding 4d Molecular Therapeutics In